Chairperson Perspective: Core Concepts for Community-Based Practice: The Evolving Role of Bispecific Antibody Therapy in Relapsed or Refractory Follicular Lymphoma
- Author
- ReachMD
- Published
- Tue 15 Apr 2025
- Episode Link
- http://reachmd.com/programs/cme/chairperson-perspective-core-concepts-for-community-based-practice-the-evolving-role-of-bispecific-antibody-therapy-in-relapsed-or-refractory-follicular-lymphoma/29191/
CME credits: 0.25
Valid until: 15-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-core-concepts-for-community-based-practice-the-evolving-role-of-bispecific-antibody-therapy-in-relapsed-or-refractory-follicular-lymphoma/29191/
Valid until: 15-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-core-concepts-for-community-based-practice-the-evolving-role-of-bispecific-antibody-therapy-in-relapsed-or-refractory-follicular-lymphoma/29191/
Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.
=